The performance of companies tied to blockbuster drugs like Viagra presents a complex investment scenario . While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the loss of exclusivity in key regions has introduced significant risk . Investors are now grappling with the effect of generic